# Source review of three live Astra runs

Review performed September 10, 2026 by a separate data/research agent. This is a bounded factual review of consequential claims, source references and limitations, not expert clinical validation or a prediction-accuracy study. Generated investigation text was not edited by this reviewer. Publication preparation should distinguish metadata sanitation from changes to the model's actual answer.

## Apitegromab — run 1086eb94-24fd-4b75-94ef-f1f8ac2227ff

**Result:** No material factual error found in the consequential claims checked.

- Verified the clinical effects and p-values against Scholar Rock's March 16 SAPPHIRE disclosure and the actual enrollment/design against the current ClinicalTrials.gov record. The answer separates the combined-dose analysis, the individual-dose analysis and the efficacy population appropriately.
- Independently queried the FDA complete-response API. It returns the September 22, 2025 letter for BLA 761463. The answer accurately describes manufacturing-compliance conditions, possible additional inspection, labeling/safety updates and a conditional pregnancy-safety requirement. It does not invent observed pregnancy harm or convert routine requested updates into a new efficacy failure.
- Checked the August 7 facility announcement. The answer attributes alternative-site inspections and readiness statements to the sponsor, acknowledges the unnamed replacement facility, and distinguishes site transfer mitigation from completed FDA acceptance.
- The April Form 483 supports the listed categories of control deficiencies and FEI 3005949964. The answer correctly declines to assign redacted lots to apitegromab or attribute findings to the replacement site.
- The 395 on-time / 25 overdue Class 2 action counts match the current model artifact. The answer explicitly rejects their use as an individual approval probability and notes that this candidate's precise resubmission class was not verified.

**Assessment limit:** The present replacement-facility review was not independently available, so a favorable qualitative outlook remains the model's interpretation. This review verifies its evidence boundaries, not the outlook's eventual correctness.

## Deramiocel — run dbaf1062-0418-4997-ba97-2a5935a19c55

**Result:** No material factual error found in the consequential claims checked. The run retrieved substantive sources beyond the initial catalog.

- FDA's July presentation (media/193912, slide 16) confirms raw PUL difference 0.66 at p=0.24 under its analysis and 4.55 percentage points at p=0.029 under the applicant's modified analysis. The separate briefing's Table 12 contains the cited p=0.11 and p=0.045 variants. The answer correctly explains that different scales and missing-data variants are not interchangeable.
- The study/SAP sequence matches the briefing: completed blinded-period follow-up June 18, 2025; SAP 2.0 September 26; SAP 3.0 November 24; formal lock/unblinding November 25. The answer avoids claiming that this sequence proves post-unblinding manipulation.
- Capricor's August 13 update confirms the reported LVEF correction from approximately p=0.04 and 2.4 percentage points to p=0.09 and 1.8 points, with the reported subgroup p=0.02 and PUL result unchanged. It also supports the sponsor-attributed 3–9 cardiomyopathy vote and single-observation BIMO update.
- FDA reports hypersensitivity in 22/53 (41.5%) versus 8/52 (15.4%); the answer's approximate 42% and 15% are faithful rounding. It describes functional unblinding as a possibility rather than a proven failure.
- The answer distinguishes the July cardiomyopathy review from the August upper-limb amendment and properly limits what uncontrolled second-year follow-up can establish. It does not claim FDA accepted the amendment's efficacy rationale or rejected the amended indication.

**Assessment limit:** The full amendment, journal analyses and current FDA correspondence were not reviewed. Advisory-vote characterization remains sponsor-attributed. The model's guarded outlook is a qualitative judgment, not a calibrated probability.

## Apitegromab challenge — run d293d1fd-2e27-4a09-93d6-8666ad6911e3

**Result:** No material factual error found in the checked new evidence, revision or historical comparison. The challenge was a real API run, started September 10, 2026 at 17:52:01.636 UTC, with model `gpt-6-astra`, duration 124.193 seconds, 166,721 input tokens and 3,520 output tokens.

- Independently opened the newly found [August 21 sponsor release](https://investors.scholarrock.com/news-releases/news-release-details/scholar-rock-provides-update-global-apitegromab-regulatory) and its [Business Wire distribution](https://www.businesswire.com/news/home/20260821050366/en/Scholar-Rock-Provides-Update-on-Global-Apitegromab-Regulatory-Progress-Across-U.S.-Europe-and-Japan). It reports completed removal of Catalent from the U.S. BLA under FDA guidance, continuing alternative-site review and the September 30 target. The updated wording is a real advance over the August 7 source in the starting packet.
- The same release supports the reported alternative-site inspection history and inventory. It describes the European withdrawal procedure concluding August 20 and plans for resubmission. The model appropriately keeps that European event separate from a U.S. rejection and avoids asserting that the new site's manufacturing package was accepted.
- The linvoseltamab analogy is supported by [Regeneron's August 20, 2024 release](https://investor.regeneron.com/news-releases/news-release-details/regeneron-provides-update-biologics-license-application-0): a third-party fill-finish finding was the reported sole approvability issue, and reinspection was pending despite the manufacturer's belief that findings were resolved. Its [February 11, 2025 release](https://investor.regeneron.com/news-releases/news-release-details/linvoseltamab-bla-accepted-fda-review-treatment) reports resubmission acceptance following resolution and a July 10 target. [FDA confirms July 2 accelerated approval](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-linvoseltamab-gcpt-relapsed-or-refractory-multiple-myeloma).
- FDA FY2025 PDUFA report printed page 92 supports the analog's 8.0-month first review, 4.7-month sponsor response and 5.7-month second review. These figures describe that completed historical pathway. The answer explicitly notes selection from approved applications, different clinical context, no demonstrated shared facility and no basis for an individual approval probability.

**Assessment limit:** The model found additional evidence, not a complete public record. “Risk substantially mitigated” remains qualitative inference. The precise replacement site, inspection scope and product-specific FDA acceptance remain unverified. The initial catalog and first investigation were incomplete concerning the August 21 update; the challenge corrects that omission without rewriting the earlier recorded answer.

## Publication issue identified

The original local run files included search-source `summary` fields containing long verbatim page fragments. Those must not be copied into the public repository under the project's minimal-excerpt policy. Preserve complete originals in ignored runtime storage and publish source URLs, attribution, corrected source-type metadata, short paraphrases/minimal excerpts and retrieval provenance. Record that source metadata was sanitized while retaining the actual model-generated findings/outlook unchanged.

Some discovered sponsor pages were initially classified generically as `publication`, and some search dates were absent or apparent crawl dates. Where source-page dates are verified, use them; otherwise retain null rather than inventing first-public availability. Neither valid citation IDs nor a successful retrieval is proof of scientific entailment.
